<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Human Genetics</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F2D83657-5DAA-4116-8F2A-1A598AB8B26C"><gtr:id>F2D83657-5DAA-4116-8F2A-1A598AB8B26C</gtr:id><gtr:firstName>Edwin Kwan Soon</gtr:firstName><gtr:surname>Wong</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK023519%2F1"><gtr:id>9F59E99C-6D80-47FE-8CF2-7AB43D33B9F5</gtr:id><gtr:title>Genetic and Acquired Complement Abnormalities in Idiopathic Membranoproliferative Glomerulonephritis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/K023519/1</gtr:grantReference><gtr:abstractText>Idiopathic Membranoproliferative Glomerulonephritis (MPGN) is a kidney disease that predominantly affects children and young adults. It accounts for around 5% of End Stage Renal Disease (ESRD) in children.

Presently, there are no specific treatments for idiopathic MPGN and consequently there is progression to ESRD requiring long term dialysis treatment. Although renal transplantation is undertaken, MPGN usually recurs in the transplant leading to graft failure.

The pivotal role of the complement system in MPGN has been recognised for some time. Complement is an ancient defence system which coats both foreign cells (such as bacteria and viruses) and our own cells (including those of the kidney) with a substance called C3. This substance will eventually lead to the destruction of bacteria and viruses by damaging the cell wall. If our own cells are not protected against C3 they can suffer a similar fate. This is why we have a series of regulators which inactivate C3. We have, in pilot studies, found that patients with MPGN have mutations in and antibodies against a regulator called factor H. 

In this study I wish to examine whether MPGN patients have mutations in other complement genes and antibodies against other complement proteins. 

I will undertake this work in the Newcastle Renal Genetics Group (RGG). This research environment provides World leading expertise in the genetics of complement mediated renal disease and has access to a large database of patients with MPGN.

There are now specific agents to treat both complement and antibody associated diseases. Fully characterising the underlying complement defect will allow progress towards the treatment of MPGN. 

The RGG has used such a strategy to yield a successful treatment for a similar complement mediated renal disease, called atypical haemolytic uraemic syndrome. We envisage similar benefits in MPGN.</gtr:abstractText><gtr:technicalSummary>Membranoproliferative glomerulonephritis (MPGN) accounts for ~10% of biopsy proven glomerulonephritis and of the primary glomerulonephritides, is the third commonest cause of End Stage Renal Disease (ESRD). It is well established that MPGN is associated with activation of the alternative pathway (AP) of complement. Preliminary data from our lab and others suggests that autoantibodies and mutations affecting the complement system may predispose to disease.

The aims of this project are to:-

1) Establish the prevalence of inherited and acquired complement abnormalities in MPGN.

2) Analyse their functional consequences.

3) Define clinical and pathological correlates with specific complement abnormalities.

In both the Newcastle cohort of MPGN patients (currently n=40) and the MPGN cohort of RaDaR (renal Rare Disease Registry), I will screen the genes encoding factor H, factor I, membrane cofactor protein, factor B and C3 for mutations. I will also screen serum samples for autoantibodies against factor H, factor I, membrane cofactor protein, and the complement factor H related proteins.

I will assess the functional significance of identified genetic variants in CFH using recombinantly produced protein in C3b binding assays (surface plasmon resonance (SPR)), decay acceleration assays (cell surface; SPR) and in cofactor assays (fluid phase; cell surface). Complement haemolytic assays will be used to assess the functional consequences of autoantibodies to complement components. 

In these patients with complement abnormalities I will determine if there are clinical and pathological correlates. Similar studies in Newcastle on the role of the AP in pathogenesis of atypical haemolytic uraemic syndrome (aHUS) led to successful clinical trials of the complement inhibitor Eculizumab. Given the similarities with aHUS, a characterisation of the role of complement in MPGN, is likely to lead to similar translation benefits.</gtr:technicalSummary><gtr:potentialImpactText>Patients
Membranoproliferative Glomerulonephritis (MPGN) accounts for ~10% of biopsy proven glomerulonephritis and of the primary glomerulonephritides, is the third commonest cause of End Stage Renal Disease (ESRD). Presently, there are no specific treatments for idiopathic MPGN and consequently there is progression to ESRD requiring long term dialysis treatment. Although renal transplantation is undertaken, MPGN usually recurs in the transplant leading to graft failure. It is therefore important to understand the mechanisms that lead to the development of idiopathic MPGN in order to implement a rational treatment strategy.
Since the late 1990s, the Renal Genetics group in Newcastle has elucidated the role of the complement AP in the pathogenesis of aHUS. This led to successful clinical trials of the complement inhibitor Eculizumab in aHUS and its anecdotal use has now also been reported in MPGN. Given the similarities with aHUS, a characterisation of the role of complement in MPGN, is likely to lead to similar translation benefits.

NHS Screening
The NHS Northern Genetics Service is based in the Institute for Genetic Medicine. It hosts the national genetic screening service for complement genes in atypical haemolytic syndrome (aHUS). This screening service will expand to cover genetic screening in MPGN, another complement mediated renal disease.
The accommodation of both the NHS Northern Genetics Service and the Renal Genetic research group under one roof at the Institute for Genetic Medicine results in symbiotic gains. The two groups meet on a weekly basis to discuss the likely functional significance of variants of unknown significance in the light of the research team's knowledge. Additionally, research techniques, once optimised, can rapidly be transferred to the NHS lab.

Clinicians
By establishing the underlying genetic / acquired abnormality we will subsequently be able to derive genotype:phenotype correlations This will allow clinicians to better inform decisions with regards to recurrence following renal transplantation. It will also allow clinicians to screen potential familial kidney donors prior to donation.

Pharma
Currently, several pharmaceutical companies have complement inhibitors at various stages of development. The availability of a fully characterised cohort of patients with MPGN will facilitate a clinical trial of complement inhibitors in these patients.

Economic
This research will result in long term economic benefits to the NHS and to the Country. The ability to predict recurrence of MPGN following renal transplantation will allow physicians to delay transplantation until suitable agents are in place to prevent recurrence. In addition to preventing morbidity and mortality associated with transplant recurrence, it will allow better utilization of the transplant donor pool. This has cost savings for the NHS. 
Clinical trials of complement inhibitors are to be expected in these patients, with the hope of preventing renal failure in those who first present and allowing renal transplantation without recurrence in those on dialysis. Long term economic benefits will accrue from patients working and being productive for longer. The ability to host such a trial in the UK will have economic benefits associated with collaboration with the pharmaceutical industry.

Policy Makers
By establishing the underlying potential future requirement for treatment with complement inhibitors, policy makers will be able to plan for the cost of these agents with more certainty.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>209100</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Biacore users meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>09CDD5A2-5136-4FCB-88BD-1E31B6DAC79A</gtr:id><gtr:impact>An audience of around 75 delegates working with Biacore technology shared data on their own uses of this investigative technique. The meeting was open for questions and general discussion.

There was positive feedback from the organisers regarding the data shared.</gtr:impact><gtr:outcomeId>X2sYjC8GawA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MPGN patient and family conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D651095A-5154-4EA6-8774-B3656BAD39C5</gtr:id><gtr:impact>Around 90 patients, family members and clinicians with MPGN or an interest in MPGN attended an information and support day. I gave one talk during the day. Question and discussion was held too.

Patients and family members were invited to form a support group.</gtr:impact><gtr:outcomeId>KEc4m7dY4ve</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.mpgn.org.uk/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Genetics Matters Patient Day (Newcastle)</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9B135EB2-B78E-4C81-A925-8FFB7E44E09C</gtr:id><gtr:impact>The patient engagement team organised a 'Genetic Matters' day at the Institute of Genetic Medicine, Newcastle University on 27th February 2016, ahead of Rare Diseases Day. I described my work to small groups of the public during two 1.5 hour long round table sessions. the audience asked questions and took part in discussion about my work.</gtr:impact><gtr:outcomeId>56d80ec031a269.14441138</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Atypical HUS Patient Group (London)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1A7E1CA2-1DE6-493F-A500-51521E9BCC84</gtr:id><gtr:impact>This was an atypical haemolytic uraemic syndrome (aHUS) patient conference. Approximately 100 attended, including patients with atypical haemolytic uraemic syndrome and family members attended a patient conference. Delegates were mostly from the UK but included representatives from patients groups from around the world. This meeting was designed to inform the patient group of latest updates in the research into aHUS. I have a talk on pregnancy and aHUS. It sparked questions from healthcare professionals and patients. It was recorded and the video has since been uploaded onto youtube.</gtr:impact><gtr:outcomeId>56d80a6f9d89f3.56822005</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>https://www.youtube.com/watch?v=XuxzCkFKWtk</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MPGN and C3G Rare Disease Group (London)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>257821A7-50BB-4425-BC18-206A780A257D</gtr:id><gtr:impact>Researchers and clinicians with an interest in the diseases membranoproliferative glomerulonephritis and C3 glomerulopathies attended alongside patient group representatives to discuss research in these diseases. Progress was made in determining future research strategies and writing a paper for publication.</gtr:impact><gtr:outcomeId>56d80b0632de18.34764816</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>73139FA6-97AC-45C2-B8B5-3090426D7683</gtr:id><gtr:title>Thrombotic Microangiopathy in Inverted Formin 2Mediated Renal Disease.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e14fdc471a7f645ab7c2d9aeab31012"><gtr:id>3e14fdc471a7f645ab7c2d9aeab31012</gtr:id><gtr:otherNames>Challis RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>5aaa61c7249383.30624283</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1561F763-C39D-4A1B-866A-151B5B313E38</gtr:id><gtr:title>An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ce469836eb8252651c072b01bfa55eb"><gtr:id>1ce469836eb8252651c072b01bfa55eb</gtr:id><gtr:otherNames>Nichols EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>56d80f620a1761.38761917</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28DECE26-D80B-4898-9077-79982F889B28</gtr:id><gtr:title>Making sense of the spectrum of glomerular disease associated with complement dysregulation.</gtr:title><gtr:parentPublicationTitle>Pediatric nephrology (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5d103efcc57a8cfd120843248736168"><gtr:id>a5d103efcc57a8cfd120843248736168</gtr:id><gtr:otherNames>Johnson SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0931-041X</gtr:issn><gtr:outcomeId>doi_23714_013_2559_8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9688074D-D87D-426C-A39B-79AE0D306965</gtr:id><gtr:title>Sarcoidosis presenting with hypercalcaemia following withdrawal of long-term immunosuppression in renal transplantation.</gtr:title><gtr:parentPublicationTitle>Oxford medical case reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7075d878e784982bac9c9c3349a7bb4"><gtr:id>d7075d878e784982bac9c9c3349a7bb4</gtr:id><gtr:otherNames>Wong EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2053-8855</gtr:issn><gtr:outcomeId>54510163a49a18.30779053</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57E111BB-11E7-4129-8229-B2593136F42C</gtr:id><gtr:title>Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.</gtr:title><gtr:parentPublicationTitle>Translational research : the journal of laboratory and clinical medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7075d878e784982bac9c9c3349a7bb4"><gtr:id>d7075d878e784982bac9c9c3349a7bb4</gtr:id><gtr:otherNames>Wong EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1878-1810</gtr:issn><gtr:outcomeId>54510163205a64.76381725</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B01F16F3-A349-4B12-8CCF-24BC4C6FDA8D</gtr:id><gtr:title>Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7075d878e784982bac9c9c3349a7bb4"><gtr:id>d7075d878e784982bac9c9c3349a7bb4</gtr:id><gtr:otherNames>Wong EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>545101629b9865.98843863</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E74AE74-CCF8-47FE-9288-EE916E9BB5B0</gtr:id><gtr:title>Complement therapy in atypical haemolytic uraemic syndrome (aHUS).</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7075d878e784982bac9c9c3349a7bb4"><gtr:id>d7075d878e784982bac9c9c3349a7bb4</gtr:id><gtr:otherNames>Wong EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>doi_23714_013_05_224</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0801B1D-9485-405B-8845-C364146E083D</gtr:id><gtr:title>Hemolytic Uremic Syndrome in Pregnancy and Postpartum.</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f01475375ffd232e94263a5d7a9c2d0f"><gtr:id>f01475375ffd232e94263a5d7a9c2d0f</gtr:id><gtr:otherNames>Bruel A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn><gtr:outcomeId>5aaa61a32e9a47.39406497</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>992E1CE4-81E8-4893-8EB1-EA462EADC6A6</gtr:id><gtr:title>The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cf190801a009a97de3a4018536a7f03"><gtr:id>6cf190801a009a97de3a4018536a7f03</gtr:id><gtr:otherNames>Phillips EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>56d80f61d3df21.34531147</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E7C1B8D-85C0-4631-A769-A8F3576C3869</gtr:id><gtr:title>Whole-exome sequencing identifies rare, functional CFH variants in families with macular degeneration.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33f8b5eefa1739d60bdb71d6a13794da"><gtr:id>33f8b5eefa1739d60bdb71d6a13794da</gtr:id><gtr:otherNames>Yu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>54510162e22f45.97228937</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>275D0F42-8262-45AE-BA59-24DC7F088273</gtr:id><gtr:title>Disease-linked mutations in factor H reveal pivotal role of cofactor activity in self-surface-selective regulation of complement activation.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9567ef72e4e2aa025cba8f1272c80d1"><gtr:id>e9567ef72e4e2aa025cba8f1272c80d1</gtr:id><gtr:otherNames>Kerr H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>5aaa6219cb63e3.67325448</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C852B89D-CC36-4F4C-A529-B1701B3C95B2</gtr:id><gtr:title>Atypical haemolytic uraemic syndrome associated with amutation triggered by</gtr:title><gtr:parentPublicationTitle>Clinical kidney journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fceef557335711a02806ed80173ae569"><gtr:id>fceef557335711a02806ed80173ae569</gtr:id><gtr:otherNames>Brocklebank V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2048-8505</gtr:issn><gtr:outcomeId>545101636df068.93282348</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2214F106-276C-4BDB-9C6E-08039A511029</gtr:id><gtr:title>Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fceef557335711a02806ed80173ae569"><gtr:id>fceef557335711a02806ed80173ae569</gtr:id><gtr:otherNames>Brocklebank V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>5aaa61f4a331b9.59772387</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23A2EF7C-ABAE-4C8A-BF68-1227D3E05FC6</gtr:id><gtr:title>Diseases of complement dysregulation-an overview.</gtr:title><gtr:parentPublicationTitle>Seminars in immunopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d794c3760ba53eee3cb67cf96074927"><gtr:id>1d794c3760ba53eee3cb67cf96074927</gtr:id><gtr:otherNames>Wong EKS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1863-2297</gtr:issn><gtr:outcomeId>5aaa62464e0423.91829980</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C6174BE-8D1A-403B-8230-A3D22D95EF97</gtr:id><gtr:title>Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS).</gtr:title><gtr:parentPublicationTitle>Immunobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af5e6b57f8da59450000f65c87f050fc"><gtr:id>af5e6b57f8da59450000f65c87f050fc</gtr:id><gtr:otherNames>Wong E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0171-2985</gtr:issn><gtr:outcomeId>56d80f623707f5.66103822</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C60F9EA8-7D24-41D4-B605-31A998C2AAA7</gtr:id><gtr:title>A De Novo Deletion in the Regulators of Complement Activation Cluster Producing a Hybrid Complement Factor H/Complement Factor H-Related 3 Gene in Atypical Hemolytic Uremic Syndrome.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e14fdc471a7f645ab7c2d9aeab31012"><gtr:id>3e14fdc471a7f645ab7c2d9aeab31012</gtr:id><gtr:otherNames>Challis RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>5aaa89ab2056a0.19245105</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K023519/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>2EEE0958-6BE1-4D16-B86B-5D954CD37219</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Renal and Urogenital</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>